Clinical utility of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Lim, Yoojoo [1 ]
Kim, Sheehyun [5 ]
Kang, Jun-Kyu [1 ,2 ]
Kim, Hwang-Phil [2 ,6 ]
Roh, Hanseong [1 ]
Kim, Su Yeon [1 ]
Lee, Dongin [3 ]
Bang, Duhee [1 ,3 ]
Jeong, Seung-Yong [4 ]
Park, Kyu Joo [4 ]
Han, Sae-Won [5 ,6 ]
Kim, Tae-You [1 ,5 ,6 ]
机构：
[1] IMBdx Inc, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Genom Med, Seoul, South Korea
[3] Yonsei Univ, Dept Chem, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Dept Surg, Seoul, South Korea
[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[6] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO41-4
引用
收藏
页码：S507 / S507
页数：1
相关论文
共 50 条
  • [31] Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).
    Benavides, Manuel
    Alcaide, Julia
    Alvarez, Martina
    Torres, Esperanza
    Sevilla, Isabel
    Calle, Silvia Gil
    Reyna, Carmen
    Ales, Inmaculada
    Duran, Gema
    Wolman, Roberto
    Cazorla, Mireya
    Gallego, Pedro Jimenez
    Lopez, Irene
    Cantero, Alexandra
    Godoy, Ana
    Lanman, Richard B.
    Faull, Iris
    Odegaard, Justin
    Kim, Il Jin
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Study of circulating tumor DNA (ctDNA) of RAS-wild metastatic colorectal cancer (mCRC) as a tool for on-site mutation screening: A prospective study.
    Sawada, Takeshi
    Nakamura, Keishi
    Takahashi, Naoki
    Kubota, Eiji
    Sugiyama, Manabu
    Nakano, Shunsuke
    Ichijo, Toshimitsu
    Sakai, Rie
    Numai, Daisuke
    Nakanishi, Hiroyoshi
    Inagaki, Satoko
    Wakita, Shigenori
    Ota, Ryosuke
    Hasatani, Kenkei
    Tsuji, Kunihiro
    Doyama, Hisashi
    Izawa, Naoki
    Tsuyada, Akihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation.
    Chee, Bryant
    Ibrahim, Faaiz
    Esquivel, Mikaela
    Van Seventer, Emily E.
    Jarnagin, Joy X.
    Zhang, Li
    Ju, Jin Hyun
    Price, Kristin Sedgwick
    Raymond, Victoria M.
    Corvera, Carlos U.
    Hirose, Kenzo
    Nakakura, Eric K.
    Van Loon, Katherine
    Corcoran, Ryan Bruce
    Parikh, Aparna Raj
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).
    Yaung, Stephanie
    Tikoo, Nalin
    Nicholas, Alan
    Sommer, Nicolas
    Bendell, Johanna C.
    Hurwitz, Herbert
    Price, Richard
    Palma, John F.
    Lee, John J.
    Casey, Fergal
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] POTENTIAL CLINICAL APPLICATIONS OF CIRCULATING TUMOUR DNA (CTDNA) IN COLORECTAL CANCER
    Tie, Jeanne
    Wong, Hui-Li
    Wong, Rachel
    Diaz, Luis A., Jr.
    Papadopoulos, Nickolas
    Strausberg, Robert
    Kinzler, Kenneth
    Vogelstein, Bert
    Gibbs, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 11 - 11
  • [36] Clinical utility of circulating tumor DNA (ctDNA) in patients with early/resected biliary tract cancer (BTC)
    Yu, J.
    Mehta, R.
    Anaya, D.
    Denbo, J.
    Bridges, C.
    Manage, K.
    Tin, A.
    Aushev, V.
    Sharma, S.
    Jurdi, A.
    Liu, M.
    Kim, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S55 - S56
  • [37] Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer.
    Morris, Van K.
    Raghav, Kanwal Pratap Singh
    Dasari, Arvind
    Overman, Michael J.
    Kee, Bryan K.
    Johnson, Benny
    Parseghian, Christine Megerdichian
    Shen, John Paul Y. C.
    Huey, Ryan
    Raymond, Victoria M.
    Duose, Dzifa Yawa
    Luthra, Rajyalakshmi
    Hong, David S.
    Janku, Filip
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
    Santos Vivas, C.
    Vidal Barrull, J.
    Fernandez Rodriguez, C.
    Salva Ballabrera, F.
    Alonso-Orduna, V.
    Garcia-Carbonero, R.
    Losa, F.
    Tarazona Llavero, N.
    Safont Aguileria, M. J.
    Rivera Herrero, F.
    Layos Romero, L.
    Ortiz Morales, M. J.
    Salud, A.
    Alcaide-Garcia, J.
    Paez, D.
    Hernandez-Yague, X.
    Alvarez Gallego, R.
    Vera, R.
    Bellosillo Paricio, B.
    Montagut Viladot, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S433 - S434
  • [39] A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D)
    Raghav, Kanwal Pratap Singh
    Wang, Xin Shelley
    Xiao, Lianchun
    Dasari, Arvind
    Morris, Van K.
    Johnson, Benny
    Shen, John Paul Y. C.
    Parseghian, Christine Megerdichian
    Kee, Bryan K.
    Shureiqi, Imad
    Fogelman, David R.
    Wolff, Robert A.
    Raymond, Victoria M.
    Odegaard, Justin I.
    Lanman, Richard B.
    Overman, Michael J.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
    Sunakawa, Y.
    Usher, J.
    Satake, H.
    Jaimes, Y.
    Miyamoto, Y.
    Nakamura, M.
    Kataoka, M.
    Shiozawa, M.
    Takagane, A.
    Terazawa, T.
    Watanabe, T.
    Ishigure, K.
    Tanaka, C.
    Sekikawa, T.
    Takeuchi, M.
    Fujii, M.
    Danenberg, K.
    Danenberg, P. V.
    Lenz, H-J.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2018, 29
12345